J Clin Oncol: Efficacy and safety of CMB305 combined with atezolizumab in the treatment of locally advanced synovial sarcoma or myxoid liposarcoma

Therapeutic vaccination of cancer should induce effective, stable, and self-renewing T cells that can directly target specific tumor-associated antigens
.

CMB305 is a heterologous primary immunization-boost vaccination program, which is used to primarily immunize the NY-ESO-1 specific CD8 T cell population, and then activate the immune response with an effective TLR-4 agonist

immunity

This is an open-label randomized phase 2 trial designed to evaluate the efficacy and safety of the CMB305 regimen combined with atezolizumab compared with atezolizumab alone for patients with synovial sarcoma or myxoid liposarcoma
.

Sant P.
Chawla, et al.
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Journal of Clinical Oncology

Sant P.
Chawla, et al.
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Journal of Clinical Oncology

Patients with locally advanced, recurrent or metastatic synovial sarcoma or myxoid liposarcoma were recruited and randomly divided into two groups to receive CMB305 combined with atezolizumab (experimental group) or atezolizumab alone (control group).

.

The primary endpoints are progression-free survival (PFS) and overall survival (OS)

PFS and OS of the two groups

PFS and OS of the two groups

A total of 89 patients were recruited; 55.
1% of patients had received at least 2 line chemotherapy in the past
.

The median PFS of the combination group and the control group were 2.

The median PFS of the combination group and the control group were 2.

Survival prognosis of patients with or without anti-NY-ESO-1 T cell immune response

Survival prognosis of patients with or without anti-NY-ESO-1 T cell immune response

In a post-hoc analysis of patients receiving various doses, the subgroup of patients who obtained an anti-NY-ESO-1 T cell immune response had longer OS (36 months; HR 0.
3; p=0.
02)
.

In the post-hoc analysis of patients receiving various doses, the OS of the subgroup of patients who obtained anti-NY-ESO-1 T cell immune response was longer.
In the post-hoc analysis of patients receiving various doses, anti-NY was obtained.
-ESO-1 T cell immune response patient subgroup has longer OS

In summary, although compared with atezolizumab alone, CMB305 combined with atezolizumab did not significantly prolong the PFS and OS of patients with synovial sarcoma or myxoid liposarcoma; some patients showed anti-NY-ESO- 1 Evidence of an immune response, and seems to have a better prognosis than patients without such an immune response
.

The combined program deserves further evaluation in other clinical remissions

Although compared with atezolizumab alone, CMB305 combined with atezolizumab did not significantly prolong PFS and OS in patients with synovial sarcoma or myxoid liposarcoma; some patients showed evidence of anti-NY-ESO-1 immune response , And seems to have a better prognosis than patients without this immune response

Original source:

Sant P.

Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1 in this message